Cellectis Partners with Sanofi for Anti-CD52 Antibody Alemtuzumab Over ALLO-647; Could Sanofi Apply Alemtuzumab Learnings to Kiadis’s Pipeline?
On Tuesday, May 11, Cellectis announced (press release) a partnership and supply agreement with Sanofi for alemtuzumab (anti-CD52 monoclonal antibody) as a lymphodepletion agent for allogeneic CAR-Ts. Below, Celltelligence provides insights on how Sanofi may leverage Cellectis’s collaboration to increase their presence within the cell therapy space while discussing Cellectis’s choice of alemtuzumab over Allogene’s ALLO-647 as a lymphodepleting agent in their clinical programs.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.